Skip to main content
. 2023 Jul 3;14:1185570. doi: 10.3389/fimmu.2023.1185570

Figure 9.

Figure 9

Guizhi Fuling capsule (GZFL) inhibits neuroinflammatory responses in LPS-stimulated primary microglia by intercepting the JAK2/STAT3 signaling pathway. Control (Ctrl): untreated primary microglia. LPS: LPS (100 ng/ml) stimulation alone. LPS+GZFL: combined treatment of LPS (100 ng/ml) and GZFL (50 μg/ml). LPS+Ruxolitinib: combined treatment of LPS (100 ng/ml) and Ruxolitinib (5 μM). LPS+C188-9: combined treatment of LPS (100 ng/ml) and C188-9 (10 μM). LPS+GZFL+Ruxolitinib: combined treatment of LPS (100 ng/ml), GZFL (50 μg/ml) and Ruxolitinib (5 μM). LPS+GZFL+C188-9: combined treatment of LPS (100 ng/ml), GZFL (50 μg/ml) and C188-9 (10 μM). (A) Representative Western blot for the total of JAK2, STAT3, and their respective phosphorylated levels. (B, C) Quantification of Western blot for phosphorylated JAK2 (B) and STAT3 (C). (D) Representative Western blot for the total of STAT3 and phosphorylated STAT3. (E) Quantification of Western blot for phosphorylated STAT3. (F) Representative Western blot for the expressions of iNOS and COX2. (G, H) Quantification of Western blot for iNOS (G) and COX2 (H). The expressions of phosphorylated JAK2 and STAT3 were standardized based on the respective total of JAK2 and STAT3. The protein expressions of iNOS and COX2 were standardized based on the respective expressions of β-actin. Uncropped immunoblots are shown in Supplementary Figure 5 . These values were showed as relative changes to the respective Control, which was set to 1. Data are the mean ± SEM from three independent experiments, ***P < 0.001 vs untreated Controls; ###P < 0.001 vs LPS alone.